Journal of Vaccine Research 2024, Vol.14, No.4, 207-216 http://medscipublisher.com/index.php/jvr 209 computational modeling have enabled the precise design of antigens that can target multiple pathogens simultaneously. This includes the development of chimeric antigens that combine epitopes from different pathogens, offering the potential to elicit robust and broad immune responses (de la Fuente and Contreras, 2021). Enhanced delivery systems, such as lipid nanoparticles and viral vectors, have improved the stability and immunogenicity of these antigens, ensuring their effective delivery to the immune system (Zhou et al., 2020). Additionally, the development of novel adjuvants has been critical in boosting the immune response, especially when dealing with complex multi-pathogen formulations (Pulendran et al., 2021). These adjuvants are designed to modulate the immune system selectively, enhancing the desired immune response while minimizing side effects (Rauch et al., 2018). 2.2 Preclinical and clinical developments Several multi-pathogen vaccine candidates are currently in various stages of preclinical and clinical development. These vaccines are designed to provide immunity against multiple diseases, reducing the need for multiple vaccinations and simplifying immunization schedules (Zaman et al., 2021). For instance, some candidates are being tested for their ability to protect against both COVID-19 and influenza, combining antigens from both viruses into a single vaccine formulation. Other candidates are focused on addressing tropical diseases, such as a multi-pathogen vaccine targeting dengue, Zika, and chikungunya viruses (Bhardwaj et al., 2023; Mba et al., 2023; Tognetti et al., 2023). These vaccines are being tested for safety, immunogenicity, and efficacy, with promising results emerging from early-phase trials (Flaxman et al., 2024). Understanding the immune response mechanisms induced by multi-pathogen vaccines is crucial for evaluating their efficacy. Studies have shown that these vaccines can induce both humoral and cellular immune responses, providing comprehensive protection against multiple pathogens. For instance, mRNA-based multi-pathogen vaccines have been found to elicit strong T-cell responses, which are essential for long-term immunity and cross-protection against related pathogens (Lopez-Siles et al., 2021; Gilbert et al., 2022). Clinical trials have also demonstrated that these vaccines can achieve high efficacy rates, similar to or exceeding those of traditional single-pathogen vaccines, making them a promising tool in the global fight against infectious diseases (Khan et al., 2022). 2.3 Multi-Pathogen vaccine efficacy The efficacy of multi-pathogen vaccines is closely linked to their ability to generate cross-protection across different pathogens. This is achieved through the careful selection and design of antigens that can induce immune responses capable of recognizing and neutralizing multiple related pathogens (Figure 2). Studies have highlighted the importance of understanding antigenic cross-reactivity and the role of adjuvants in enhancing cross-protection (Bergmann et al., 2022). Additionally, the integration of systems biology approaches has allowed researchers to predict and optimize immune responses, ensuring that multi-pathogen vaccines provide broad and effective protection (Yenkoidiok-Douti and Jewell, 2020). Preclinical studies have demonstrated that these vaccines can induce robust immune responses against multiple pathogens simultaneously, paving the way for their further development and eventual clinical use. 3 Challenges in Multi-Pathogen Vaccine Development 3.1 Scientific and technical challenges One of the most significant scientific challenges in the development of multi-pathogen vaccines is the issue of antigenic interference and immunodominance. When multiple antigens are combined within a single vaccine, there is a risk that the immune system may not respond equally to all the antigens. This phenomenon, known as immunodominance, occurs when the immune system predominantly targets one or a few antigens, potentially leading to weaker or ineffective responses to others (Lopez-Siles et al., 2021). Additionally, antigenic interference can occur when the presence of one antigen affects the immune response to another, potentially reducing the overall efficacy of the vaccine. Addressing these issues requires sophisticated antigen design strategies that can ensure all targeted pathogens elicit strong and effective immune responses without interference (Jones and Ponomarenko, 2022; Tognetti et al., 2023).
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==